Vendor Intelligence Report: Peptidology

Executive summary

Peptidology is a peptide-by-peptide decision, not a blanket green light. Across 16 Finnrick lab tests, the current record is 12 pass / 4 fail, an overall pass rate of 75%. GHK-Cu is the strongest argument for buying here, PT-141 is directionally more defensible, BPC-157 is the clear weak point, and Ipamorelin remains conditional. The report also shows how comfort margins change under stricter grading.

The corporate trail complicates the brand story. Formation, trademark and archive records point to a newly formed Arizona LLC behind Peptidology, while archived legal text reviewed by Finnrick did not name that entity. The visible rollout begins in the late-2024/early-2025 window, making claims such as “Trusted by 29,000+ researchers,” “FDA audited suppliers,” and “cGMP-aligned manufacturing” claims to verify rather than assume.

The strongest non-lab safety signal comes from vendor-linked Reddit activity: a 12% batch-rejection admission in the context of sterility failures, plus discussion of overseas sourcing, border friction and high-risk payment processing. The buyer control is practical: require lot-specific COAs, verify them with the named lab, and preserve payment methods that keep dispute rights intact.

There is balance. No public FDA Warning Letter or Peptidology-specific litigation was found in the supplied trail, and the scan did not find a broad X-based affiliate push. But the founder’s parallel peptide-vendor consulting role, Shopify-to-WooCommerce migration, MATCH/TMF-specific commentary and uneven affiliate disclosure all affect how much weight to give vendor-facing claims.

Inside the full report:

• Per-product pass/fail rates, methodology-divergence charts and rating trajectories for all four Finnrick-tested products
• Arizona entity, USPTO trademark, address and Wayback timeline tying the brand to its operating structure
• Archived homepage, soft-launch, author-page, legal-text and “Our Company” claim captures
• Reddit evidence covering sterility failures, 12% batch rejection, overseas sourcing and MATCH/TMF payment-rail discussion
• Peptide Startups dual-role conflict analysis, personnel identifiers and infrastructure footprint
• Affiliate/promotion scan, Trustpilot safety signals and FDA Warning Letter search results

Risk assessment

• BPC-157 product-quality risk — high: Finnrick’s BPC-157 record is 3 tests, 0 pass / 3 fail, with a current rating of 40.65%; do not generalize stronger GHK-Cu/PT-141 results to this product.
• Ipamorelin product-quality risk — medium: Finnrick’s Ipamorelin record is mixed at 3 tests, 2 pass / 1 fail, with a current rating of 68.74%; require current lot-specific verification.
• Sterility and batch-rejection disclosure risk — high: The founder-linked Reddit account stated “We’re rejecting 12% of batches now” while discussing sterility failures on some vials; affected products, suppliers, and corrective actions are not disclosed.
• Marketing-claim substantiation risk — medium: Claims including “29,000+ researchers,” “FDA audited suppliers,” “cGMP-aligned manufacturing,” and “pharmaceutical-grade” were not independently verified against the young entity/domain timeline.
• Corporate-conflict and transparency risk — medium: Nine of One LLC is tied to the trademark/address but not named in archived legal text; the founder also operates Peptide Startups, advising peptide-market entrants on sourcing, payments, and compliance.
• Payment-processing and chargeback risk — medium: Archived terms list crypto/Zelle/bank transfers alongside cards, the site migrated from Shopify, and the vendor account discussed MATCH/TMF removal; an actual MATCH listing is not confirmed.
• Affiliate-promotion risk — medium: Project Biohacking promoted Peptidology with code PROBIO15 and a referral link without clear disclosure in the scan; Peptide Critic’s support disclosure was clearer.